Clinical Trial Update: Comparison of New-onset Diabetes After Transplantation Between Two Steroid Withdrawal Group With CellCept [NA]

View source ↗

Summary

Clinical trial update comparing two steroid-withdrawal regimens in transplant patients receiving CellCept, focusing on new-onset diabetes after transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Samsung Medical Center | Conditions: Diabetes | NA | Status: UNKNOWN